Pirruccello, S.J., Jackson, J.D., Lang, M.S., DeBoer, J., Mann, S., Crouse, D., Vaughan, W.P., Dicke, K.A. and Sharp, J.G. (1992) OMA-AML-1: A leukemic myeloid cell line with CD34+ progenitor and CD15+ spontaneously differentiating cell compartments. Blood, 80, 1026-1032.

has been cited by the following article:

• TITLE: Characterization of a mesenchymal stem cell line that differentiates to bone and provides niches supporting mouse and human hematopoietic stem cells

  AUTHORS: Sonal R. Tuljapurkar, John D. Jackson, Susan K. Brusnahan, Barbara J. O’Kane, John G. Sharp

  KEYWORDS: Bone; Cell Therapy; Hematopoiesis; MSC; Regenerative Medicine; Stem Cells

  JOURNAL NAME: Stem Cell Discovery, Vol.2 No.1, December 31, 2011

  ABSTRACT: Identification of mouse cell lines with properties of primary multipotential mesenchymal stromal cells (MSC) is required to facilitate the use of mouse models for evaluation of mechanisms in bone formation, hematopoiesis and cellular therapies for regenerative medicine. Primary murine MSC vary between strains, are difficult to grow in vitro and have inconsistent properties. The main aim of the study was to establish OMA-AD cells as an appropriate model system to conduct studies on MSC, bone formation and hematopoiesis. OMA-AD cells were isolated by differential trypsinization of C57BL/6J mouse bone marrow (BM) cells. The cells were then repassaged, cloned and characterized. OMA-AD cells were immortal and non-tumorigenic, differentiated readily to all mesenchymal cell types including bone, supported mouse and human hematopoiesis and were immunosuppressive. Our results demonstrated that OMA-AD cells possessed the properties of primary MSC. In addition, these cells grew readily and consistently, thereby facilitating future studies of bone formation, hematopoiesis and mesenchymal cells for regenerative medicine.